Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurodegenerative disorders therapeutics - BioArctic Neuroscience

Next Previous
Drug Profile

Research programme: neurodegenerative disorders therapeutics - BioArctic Neuroscience

Alternative Names: AD-0802; AD-1502; AD-2203; AE-1501; BAN-2203; BAN-2502; BAN2401 back-up

Latest Information Update: 18 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioArctic Neuroscience
  • Developer BioArctic
  • Class Antidementias; Antiparkinsonians; Monoclonal antibodies; Vaccines
  • Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 14 Nov 2022 The US PTO grants a new platform patent for a technology for transporting biopharmaceuticals across the blood-brain barrier in USA
  • 28 Oct 2022 No recent reports of development identified for research development in Parkinson's-disease in Sweden (Parenteral)
  • 20 Apr 2022 AbbVie terminated the collaboration with BioArctic regarding the portfolio of alpha-synuclein antibodies, including ABBV 0805
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top